Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

RedHill Biopharma Reports Results for the Second Quarter of 2015

GlobeNewswire July 29, 2015

RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals

GlobeNewswire July 27, 2015

RedHill Biopharma to Host Second Quarter 2015 Financial Results Conference Call on July 29, 2015

GlobeNewswire July 23, 2015

RedHill Biopharma to Host Second Quarter 2015 Financial Results Conference Call on July 29, 2015

GlobeNewswire July 23, 2015

RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares

GlobeNewswire July 22, 2015

RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares

GlobeNewswire July 22, 2015

RedHill Biopharma Prices Public Offering of Its American Depository Shares

GlobeNewswire July 16, 2015

RedHill Biopharma Announces Size of Proposed Public Offering of Its American Depository Shares

GlobeNewswire July 15, 2015

RedHill Biopharma Extends Option Agreement for Phase II-Stage Pancreatic Cancer Drug RP101

GlobeNewswire July 15, 2015

RedHill Biopharma Announces Proposed Public Offering of Its American Depository Shares

GlobeNewswire July 14, 2015

RedHill Biopharma Receives Authorization in Australia and New Zealand for Ongoing Phase III Crohn's Disease Study With RHB-104

GlobeNewswire July 6, 2015

RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program

GlobeNewswire July 1, 2015

RedHill Biopharma Initiates Phase I/II Study of ABC294640 for Refractory Lymphoma

GlobeNewswire June 29, 2015

RedHill Biopharma Announces Acceptance of Phase III Trial Application in Europe with RHB-104 for Crohn's Disease

GlobeNewswire June 16, 2015

RedHill Biopharma to Present at the 2015 BIO International Convention

GlobeNewswire June 16, 2015

RedHill Biopharma to Host Conference Call Today to Review Positive Phase III Top-Line Results With RHB-105 for H. Pylori Infection

GlobeNewswire June 15, 2015

RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection

GlobeNewswire June 15, 2015

RedHill Biopharma Announces Completion of Patient Enrollment in the Phase IIa Study of RHB-104 for Multiple Sclerosis

GlobeNewswire June 9, 2015

RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study

GlobeNewswire June 8, 2015

RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results

GlobeNewswire June 3, 2015